echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > And Platinum Pharmaceuticals jointly announced the launch of AbbVie's new Coronary Antibody Phase 1 clinical trial

    And Platinum Pharmaceuticals jointly announced the launch of AbbVie's new Coronary Antibody Phase 1 clinical trial

    • Last Update: 2021-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Phase I clinical trials will be a randomized, double-blind, placebo-controlled study designed to assess the safety, pharmacodynamics, and pharmacodynamics of ABBV-47D11 in a single dose climb in COVID-19 adult hospitalized populations.
    the trial will be tested in three dose groups on 24 patients at multiple research bases around the world, with the main endpoints assessing drug-related adverse events and setting up multiple secondary endpoints.
    in preclinical studies, the antibody showed the potential to block SARS-CoV-2 and SARS-CoV-1 infections.
    under the equity introduction agreement, AbbVie will be responsible for the clinical study of ABBV-47D11 and, if successful, for the global production and commercialization process.
    at the same time, AbbVie will pay a one-time equity transfer fee and a phased fee for the development, regulation and sale of the antibody's equity to Platinum Pharmaceuticals and the University of Ulysses, as well as a tiered royalty on net commercial sales.
    university medical center in Therasmus was involved in the basic science section of the study and did not participate in the signing of the authorization agreement.
    remaining terms have not been disclosed.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.